JR Lillehaug

510 citations
7 papers · 419 indexed · h-index 6
Topics
HER2/EGFR in Cancer Research (3 papers)Glycosylation and Glycoproteins Research (3 papers)Cancer-related gene regulation (2 papers)
Partner nations
NorwaySwedenSudan

In The Last Decade

JR Lillehaug

7 papers receiving 403 citations

Peers

JR Lillehaug
Comparison fields: 5 of 72
  • Oncology 205
  • Molecular Biology 188
  • Endocrinology, Diabetes and Metabolism 84
  • Radiology, Nuclear Medicine and Imaging 67
  • Cancer Research 56
Replace Patel Dd with:
Patel Dd India
Peter Mu‐Hsin Chang Taiwan
Li E. Wang United States
Pei‐Yu Huang China
F. Mihaimeed United Kingdom
Yingying Huang China
Tomotaka Shibata Japan
André Vasconcelos Portugal
Yukari Ishiguro Japan
Arlita Pang United States
JR Lillehaug relative to Patel Dd India Patel Dd's profile →
Citations per field
00.5×5.6×
Patel Dd · 1×
Citations per year

Countries citing papers authored by JR Lillehaug

Since Specialization
Citations

This map shows the geographic impact of JR Lillehaug's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JR Lillehaug with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JR Lillehaug more than expected).

Fields of papers citing papers by JR Lillehaug

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JR Lillehaug. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JR Lillehaug. The network helps show where JR Lillehaug may publish in the future.

Co-authorship network of co-authors of JR Lillehaug

This figure shows the co-authorship network connecting the top 25 collaborators of JR Lillehaug. A scholar is included among the top collaborators of JR Lillehaug based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JR Lillehaug. JR Lillehaug is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
#WorkIndexed citations
1 47
2 29
3
Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck.
63
4 114
5 1
6 67
7 98

About JR Lillehaug

JR Lillehaug is a scholar working on Otorhinolaryngology, Oncology and Dermatology, having authored 7 papers that have together received 419 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (3 papers), Glycosylation and Glycoproteins Research (3 papers) and Cancer-related gene regulation (2 papers). The work is most often cited by research in Periodontics (43 citations), Otorhinolaryngology (35 citations) and Oncology (205 citations). JR Lillehaug has collaborated with scholars based in Norway, Sweden and Sudan. Frequent co-authors include JE Varhaug, A. C. Johannessen, Rune Nilsen, Per Gunnar Liavaag, Dagny Faksvåg Haugen, Rune Male, Rein Aasland, Kjell Kleppe, Bengt Magnusson and Endre N. Vasstrand. Their work appears in journals such as British Journal of Cancer, Annals of Oncology and Oral Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026